Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function

Infection and Immunity

Volumn 83, Issue 1, 2015, Pages 138-145

  Leslie, Jhansi L ^a   Huang, Sha ^a   Opp, Judith S ^a   Nagy, Melinda S ^a   Kobayashi, Masayuki ^b   Young, Vincent B ^a   Spence, Jason R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b AKITA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANAEROBE; ARTICLE; CELLULAR PARAMETERS; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL PARACELLULAR BARRIER FUNCTION; HUMAN; HUMAN CELL; HUMAN INTESTINAL ORGANOID; MORPHOLOGY; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; PLURIPOTENT STEM CELL; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; ORGAN CULTURE TECHNIQUE;

BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; ENTEROTOXINS; HUMANS; INTESTINAL MUCOSA; ORGAN CULTURE TECHNIQUES; ORGANOIDS;

EID: 84919478713     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02561-14     Document Type: Article

References (40)

1. Hall AJ, Curns A, McDonald L, Parashar U, Lopman B. 2012. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 55:216-223. http://dx.doi.org/10.1093/cid/cis386.
2. Kasendra M, Barrile R, Leuzzi R, Soriani M. 2013. Clostridium difficile toxins facilitate bacterial colonization by modulating the fence and gate function of colonic epithelium. J Infect Dis 209:1095-1104. http://dx.doi.org/10.1093/infdis/jit617.
3. Goulding D, Thompson H, Emerson J, Fairweather NF, Dougan G, Douce GR. 2009. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect Immun 77:5478-5485. http://dx.doi.org/10.1128/IAI.00551-09.
4. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2:326-334. http://dx.doi.org/10.4161/gmic.19142.
5. Lizer JT, Madson DM, Schwartz KJ, Harris H, Bosworth BT, Kinyon JM, Ramirez A. 2013. Experimental infection of conventional neonatal pigs with Clostridium difficile: a new model. J Swine Health Prod 21:22-29.
6. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. 2011. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470:105-109. http://dx.doi.org/10.1038/nature09691.
7. Du A, McCracken KW, Walp ER, Terry NA, Klein TJ, Han A, Wells JM, May CL. 2012. Arx is required for normal enteroendocrine cell development in mice and humans. Dev Biol 365:175-188. http://dx.doi.org/10.1016/j.ydbio.2012.02.024.
8. Finkbeiner SR, Zeng X-L, Utama B, Atmar RL, Shroyer NF, Estes MK. 2012. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. mBio 3:e00159-12. http://dx.doi.org/10.1128/mBio.00159-12.
9. Xue X, Ramakrishnan S, Anderson E, Taylor M, Zimmermann EM, Spence JR, Huang S, Greenson JK, Shah YM. 2013. Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology 145:831-841. http://dx.doi.org/10.1053/j.gastro.2013.07.010.
10. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. http://dx.doi.org/10.1038/nature09397.
11. McCracken KW, Howell JC, Wells JM, Spence JR. 2011. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat Protoc 6:1920-1928. http://dx.doi.org/10.1038/nprot.2011.410.
12. Sugawara S, Ito T, Sato S, Sato Y, Kasuga K, Kojima I, Kobayashi M. 2014. Identification of site-specific degradation in bacterially expressed human fibroblast growth factor 4 and generation of an aminoterminally truncated, stable form. Appl Biochem Biotechnol 172:206-215. http://dx.doi.org/10.1007/s12010-013-0544-0.
13. Bell SM, Schreiner CM, Wert SE, Mucenski ML, Scott WJ, Whitsett JA. 2008. R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 135:1049-1058. http://dx.doi.org/10.1242/dev.013359.
14. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
15. Peterson LW, Artis D. 2014. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14:141-153. http://dx.doi.org/10.1038/nri3608.
16. Bergstrom KS, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP, Ryz N, Huang T, Velcich A, Finlay BB, Chadee K, Vallance BA. 2010. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog 6:e1000902. http://dx.doi.org/10.1371/journal.ppat.1000902.
17. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. 2002. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123: 790-802. http://dx.doi.org/10.1053/gast.2002.35391.
18. Bruewer M, Hopkins AM, Hobert ME, Nusrat A, Madara JL. 2004. RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. Am J Physiol Cell Physiol 287:C327-335. http://dx.doi.org/10.1152/ajpcell.00087.2004.
19. Shen L, Turner JR. 2005. Actin Depolymerization Disrupts Tight Junctions via Caveolae-mediated Endocytosis. Mol Biol Cell 16:3919-3936. http://dx.doi.org/10.1091/mbc.E04-12-1089.
20. Nam HJ, Kang JK, Kim S-K, Ahn KJ, Seok H, Park SJ, Chang JS, Pothoulakis C, Lamont JT, Kim H. 2010. Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J Biol Chem 285:32888-32896. http://dx.doi.org/10.1074/jbc.M110.162743.
21. Du T, Alfa MI. 2004. Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis 15:83-88.
22. Madan R, Guo X, Naylor C, Buonomo EL, Mackay D, Noor Z, Concannon P, Scully KW, Pramoonjago P, Kolling GL, Warren CA, Duggal P, Petri WA. 2013. Role of leptin-mediated colonic inflammation in defense against Clostridium difficile colitis. Infect Immun 82:341-349. http://dx.doi.org/10.1128/IAI.00972-13.
23. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2010. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2:145-158. http://dx.doi.org/10.4161/gmic.2.3.16333.
24. Britton RA, Young VB. 2012. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 20:313-319. http://dx.doi.org/10.1016/j.tim.2012.04.001.
25. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. 2012. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 80:2704-2711. http://dx.doi.org/10.1128/IAI.00147-12.
26. Rolfe RD, Hentges DJ, Campbell BJ, Barrett JT. 1978. Factors related to the oxygen tolerance of anaerobic bacteria. Appl Environ Microbiol 36: 306-313.
27. Brusa T, Canzi E, Pacini N, Zanchi R, Ferrari A. 1989. Oxygen tolerance of anaerobic bacteria isolated from human feces. Curr Microbiol 19:39-43. http://dx.doi.org/10.1007/BF01568901.
28. Green L, Worthington T, Hilton A, Lambert P. 2012. The effect of oxygen on the growth characteristics and virulence of Clostridium difficile, abstr R2411. Abstr 22nd Eur. Cong. Clin. Microbiol. Infect. Dis.
29. Lukovac S, Belzer C, Pellis L, Keijser BJ, de Vos WM, Montijn RC, Roeselers G. 2014. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. mBio 5:e01438-14. http://dx.doi.org/10.1128/mBio.01438-14.
30. Wilson SS, Tocchi A, Holly MK, Parks WC, Smith JG. 13 August 2014. A small intestinal organoid model of non-invasive enteric pathogenepithelial cell interactions. Mucosal Immunol http://dx.doi.org/10.1038/mi.2014.72.
31. Chaves-Olarte E, Weidmann M, Eichel-Streiber C, Thelestam M. 1997. Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Investig 100:1734-1741. http://dx.doi.org/10.1172/JCI119698.
32. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, LaMont JT. 1995. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Investig 95:2004-2011. http://dx.doi.org/10.1172/JCI117885.
33. Hirota SA, Iablokov V, Tulk SE, Schenck LP, Becker H, Nguyen J, Al Bashir S, Dingle TC, Laing A, Liu J, Li Y, Bolstad J, Mulvey GL, Armstrong GD, MacNaughton WK, Muruve DA, MacDonald JA, Beck PL. 2012. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun 80:4474-4484. http://dx.doi.org/10.1128/IAI.00933-12.
34. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT. 1987. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93:273-279.
35. Riegler M, Sedivy R, Sogukoglu T, Castagliuolo I, Pothoulakis C, Cosentini E, Bischof G, Hamilton G, Teleky B, Feil W, Lamont JT, Wenzl E. 1997. Epidermal growth factor attenuates Clostridium difficile toxin A-and B-induced damage of human colonic mucosa. Am J Physiol 273:G1014-G1022.
36. Pruitt RN, Chumbler NM, Rutherford SA, Farrow MA, Friedman DB, Spiller B, Lacy DB. 2012. Structural determinants of Clostridium difficile toxinAglucosyltransferase activity. J Biol Chem 287:8013-8020. http://dx.doi.org/10.1074/jbc.M111.298414.
37. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA. 2001. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 69:1329-1336. http://dx.doi.org/10.1128/IAI.69.3.1329-1336.2001.
38. Groschwitz KR, Hogan SP. 2009. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allerg Clin Immunol 124:3. http://dx.doi.org/10.1016/j.jaci.2009.05.038.
39. Artis D. 2008. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8:411-420. http://dx.doi.org/10.1038/nri2316.
40. Catalioto RM, Maggi CA, Giuliani S. 2011. Intestinal epithelial barrier dysfunction in disease and possible therapeutical interventions. Curr Med Chem 18:398-426. http://dx.doi.org/10.2174/092986711794839179.